A recent analysis of studies on antidepressant research shows hidden conflicts of interest and financial ties to drug manufacturers.
Editor's Choice
Antidepressant Studies Corrupted by Pharmaceutical Company Influence, Analysis Shows
Study 329 was a clinical trial conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI antidepressant marketed as Paxil and Seroxat, in treating depressed teenagers.
It concluded that paroxetine is “generally well tolerated and effective for major depression in adolescents.” In 2001, the study was published in the Journal of the American Academy of Child and Adolescent Psychiatry.
Study 329 was funded by GlaxoSmithKline (GSK), the drug’s manufacturer.
The company greatly exaggerated the effectiveness of the drug, and downplayed how dangerous it is for teens.
Unfortunately, Study 329 is not an outlier: drug studies have long been known to be flawed, mainly because testing is conducted by the very entities that stand to profit from sales of the medications – the drug manufacturers.
Another recent study exposed just how pervasive and serious the problem is.
Delivered by The Daily Sheeple
We encourage you to share and republish our reports, analyses, breaking news and videos (Click for details).
Contributed by Jake Van Der Borne of Jake’s Anxiety and Depression Solutions.
